TORNTPHARM Share Price Target 2030

CAGR-based price projection for Torrent Pharmaceuticals Limited (TORNTPHARM) targeting 2030, derived from official NSE exchange closing prices.

Bear Case (5.9% CAGR)
Rs 5,994
2030 Target
Base Case (14.7% CAGR)
Rs 8,260
2030 Target
Bull Case (41.1% CAGR)
Rs 18,908
2030 Target

Current Market Snapshot

CMP: Rs 4,767.30
52W High: Rs 5,122.80
52W Low: Rs 4,084.60
1Y CAGR: 31.6%
3Y CAGR: 14.7%

Year-by-Year Price Projection

YearBear CaseBase CaseBull Case
2027 Rs 5,048 Rs 5,470 Rs 6,728
2028 Rs 5,346 Rs 6,275 Rs 9,494
2029 Rs 5,661 Rs 7,200 Rs 13,398
2030 Rs 5,994 Rs 8,260 Rs 18,908

Other TORNTPHARM Price Targets

2025 2026 2027 2028 2035 2040 2050

Frequently Asked Questions

What is the TORNTPHARM share price target for 2030?

Based on historical growth analysis, the TORNTPHARM share price target for 2030 ranges from Rs 5,994 (conservative) to Rs 8,260 (base case) to Rs 18,908 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.

What is the current share price of TORNTPHARM?

The current market price of TORNTPHARM (Torrent Pharmaceuticals Limited) is Rs 4,767.30. The 52-week high is Rs 5,122.80 and 52-week low is Rs 4,084.60.

Is TORNTPHARM a good stock to buy for the long term?

Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.

What methodology does BrokerLens use for TORNTPHARM price targets?

BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 5.9% CAGR), Base (14.7% CAGR), and Bull (optimistic at 41.1% CAGR). These are statistical projections, not guaranteed forecasts.

Disclaimer: Share price targets on BrokerLens are statistical CAGR projections based on historical NSE closing prices. They are NOT guaranteed outcomes, investment advice, or analyst recommendations. Past performance does not guarantee future results. Consult a SEBI-registered investment advisor before making investment decisions. Mutual fund and equity investments are subject to market risks.